Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

n Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595, SNS-032 and SNS-314, planned additional clinical testing and development efforts, the timing of enrollment in clinical trials and the announcement of clinical results. Words such as "look forward," "suggests," "may," "expects," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risk that Sunesis' drug discovery and development activities, including enrollment and reporting of results, could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for SNS-595, SNS-032 and/or SNS-314 may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials and manufacturing of SNS-595, SNS-032 and SNS-314 and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' annual report on Form 10-K for the year ended December 31, 2006 and other filings with the Securities and Exchange Commission.
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , ... August 27, 2015 , ... Inc. Magazine released ... ranking iLab Solutions as number 1,361 in growth for the three years through 2014. ... top 0.1% fastest-growing privately held organizations in the country. , “We are thrilled ...
(Date:8/26/2015)... , ... August 26, 2015 , ... ... announces today that a second US laboratory is to open in Manhattan, Kansas ... the continued partnership and long-term growth of research and development through collaboration with ...
(Date:8/26/2015)... Aug. 26, 2015  The Diabetes Research Institute ... of Miami Miller School of Medicine, announced today ... to test for the first time a novel ... This FDA approved Phase I/II study builds upon ... is an important first step toward the development ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
Breaking Biology Technology:iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... JERICHO, N.Y., March 13, 2012   Health Care ... Via Christi Health System of Wichita, Kansas has ... rate just two months after selecting and implementing ... COI disclosure process. (Logo: http://photos.prnewswire.com/prnh/20061010/NYTU194LOGO ...
... Allentown, Pa., March 13, 2012  Good Shepherd Rehabilitation ... in the rehabilitation of physical and cognitive disabilities, ... the United States. Ekso (formerly called eLEGS) is ... www.eksobionics.com ) that allows those with lower-extremity paralysis ...
... Pharma IQ has just published the results of ... management specialist with nearly half of those questioned having a ... samples. According to the survey results, 66.7 per ... as primary concerns in their current role or department: the ...
Cached Biology Technology:Conflict of Interest Management System Selected by Via Christi Health 2Conflict of Interest Management System Selected by Via Christi Health 3Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 2Good Shepherd Rehabilitation Network Becomes Third Health-Care Organization in U.S. to Have Ekso Exoskeleton 3Pharma IQ's Compound Management Survey Report 2
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... at Dana-Farber Cancer Institute and the Broad Institute of MIT ... genes that may serve as an Achilles, heel for many ... issue of the journal Cell , the researchers identified ... been identified as potential targets for cancer therapy. Unlike most ...
... A University of Toronto (U of T) team led by Engineering ... garnered third place and $40,000 (USD) for their design of a ... to the Bill & Melinda Gates Foundation,s Reinvent the Toilet Challenge, ... and affordable for people in the developing world that doesn,t have ...
... Uzuntarla from Bulent Ecevit University, Turkey, and his colleagues ... which is present in the nervous system. The article ... work has implications for explaining how noise, modulated by ... of neurons to external stimuli as part of the ...
Cached Biology News:'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 2'CYCLOPS' genes may serve as an Achilles' heel in tumor cells 3University of Toronto wins third place at the Gates Foundation's Reinvent the Toilet Challenge 2
Custom LNA Oligonucleotide synthesis ,High quality Custom LNA Oligonucleotides are available for a variety of different specialty applications and innovative products. ,Please inquire for further...
... Get better net results - with a ... and data management! The ChemStation Plus NDS ... control, data acquisition and data management, giving ... that meets your labs needs now and ...
... Solubility Service, We deliversoluble protein or ... technology yields the best soluble protein results ... each clone submitted , Powerful results on ... protein Solubility Optimization Service (SOS) uses proprietary ...
... The Schleicher & Schuell BioScience Arraying ... dedicated to custom protein and nucleic ... project teams, comprised of R&D, Engineering, ... closely with collaborators every step of ...
Biology Products: